• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of amjpatholAmerican Journal of Pathology For AuthorsAmerican Journal of Pathology SubscribeAmerican Journal of Pathology SearchAmerican Journal of Pathology Current IssueAmerican Journal of Pathology About the JournalAmerican Journal of Pathology
Am J Pathol. May 1992; 140(5): 1039–1043.
PMCID: PMC1886512

Persistent complement activation on tumor cells in breast cancer.


The neoantigens of the C5b-9 complement complex, IgG, C3, C4, S-protein/vitronectin, fibronectin, and macrophages were localized on 17 samples of breast cancer and on 6 samples of benign breast tumors using polyclonal or monoclonal antibodies and the streptavidin-biotin-peroxidase technique. All the tissue samples with carcinoma in each the TNM stages presented C5b-9 deposits on the membranes of tumor cells, thin granules on cell remnants, and diffuse deposits in the necrotic areas. When chemotherapy and radiation therapy preceded surgery, C5b-9 deposits were more intense and extended. The C5b-9 deposits were absent in all the samples with benign lesions. S-protein/vitronectin was present as fibrillar deposits in the connective tissue matrix and as diffuse deposits around the tumor cells, less intense and extended than fibronectin. IgG, C3, and C4 deposits were present only in carcinoma samples. The presence of C5b-9 deposits is indicative of complement activation and its subsequent pathogenetic effects in breast cancer.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.2M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Images in this article

Click on the image to see a larger version.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Houghton AN, Mintzer D, Cordon-Cardo C, Welt S, Fliegel B, Vadhan S, Carswell E, Melamed MR, Oettgen HF, Old LJ. Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. Proc Natl Acad Sci U S A. 1985 Feb;82(4):1242–1246. [PMC free article] [PubMed]
  • Cheung NK, Lazarus H, Miraldi FD, Abramowsky CR, Kallick S, Saarinen UM, Spitzer T, Strandjord SE, Coccia PF, Berger NA. Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol. 1987 Sep;5(9):1430–1440. [PubMed]
  • Capone PM, Papsidero LD, Croghan GA, Chu TM. Experimental tumoricidal effects of monoclonal antibody against solid breast tumors. Proc Natl Acad Sci U S A. 1983 Dec;80(23):7328–7332. [PMC free article] [PubMed]
  • Stepan DE, Bartholomew RM, LeBien TW. In vitro cytodestruction of human leukemic cells using murine monoclonal antibodies and human complement. Blood. 1984 May;63(5):1120–1124. [PubMed]
  • Bast RC, Jr, De Fabritiis P, Lipton J, Gelber R, Maver C, Nadler L, Sallan S, Ritz J. Elimination of malignant clonogenic cells from human bone marrow using multiple monoclonal antibodies and complement. Cancer Res. 1985 Feb;45(2):499–503. [PubMed]
  • Panneerselvam M, Bredehorst R, Vogel CW. Immobilized doxorubicin increases the complement susceptibility of human melanoma cells by protecting complement component C3b against inactivation. Proc Natl Acad Sci U S A. 1986 Dec;83(23):9144–9148. [PMC free article] [PubMed]
  • Bhakdi S, Tranum-Jensen J. Membrane damage by complement. Biochim Biophys Acta. 1983 Aug 11;737(3-4):343–372. [PubMed]
  • Kolb WP, Müller-Eberhard HJ. Neoantigens of the membrane attack complex of human complement. Proc Natl Acad Sci U S A. 1975 May;72(5):1687–1689. [PMC free article] [PubMed]
  • Biesecker G, Katz S, Koffler D. Renal localization of the membrane attack complex in systemic lupus erythematosus nephritis. J Exp Med. 1981 Dec 1;154(6):1779–1794. [PMC free article] [PubMed]
  • Falk RJ, Dalmasso AP, Kim Y, Tsai CH, Scheinman JI, Gewurz H, Michael AF. Neoantigen of the polymerized ninth component of complement. Characterization of a monoclonal antibody and immunohistochemical localization in renal disease. J Clin Invest. 1983 Aug;72(2):560–573. [PMC free article] [PubMed]
  • Vlaicu R, Niculescu F, Rus HG, Cristea A. Immunohistochemical localization of the terminal C5b-9 complement complex in human aortic fibrous plaque. Atherosclerosis. 1985 Nov;57(2-3):163–177. [PubMed]
  • Mollnes TE, Lea T, Mellbye OJ, Pahle J, Grand O, Harboe M. Complement activation in rheumatoid arthritis evaluated by C3dg and the terminal complement complex. Arthritis Rheum. 1986 Jun;29(6):715–721. [PubMed]
  • Bhakdi S, Roth M. Fluid-phase SC5b-8 complex of human complement: generation and isolation from serum. J Immunol. 1981 Aug;127(2):576–580. [PubMed]
  • Podack ER, Preissner KT, Müller-Eberhard HJ. Inhibition of C9 polymerization within the SC5b-9 complex of complement by S-protein. Acta Pathol Microbiol Immunol Scand Suppl. 1984;284:89–96. [PubMed]
  • Bhakdi S, Käflein R, Halstensen TS, Hugo F, Preissner KT, Mollnes TE. Complement S-protein (vitronectin) is associated with cytolytic membrane-bound C5b-9 complexes. Clin Exp Immunol. 1988 Dec;74(3):459–464. [PMC free article] [PubMed]
  • Bhakdi S, Muhly M, Roth M. Preparation and isolation of specific antibodies to complement components. Methods Enzymol. 1983;93:409–420. [PubMed]
  • Dahlbäck K, Löfberg H, Dahlbäck B. Localization of vitronectin (S-protein of complement) in normal human skin. Acta Derm Venereol. 1986;66(6):461–467. [PubMed]
  • Niculescu F, Rus HG, Vlaicu R. Immunohistochemical localization of C5b-9, S-protein, C3d and apolipoprotein B in human arterial tissues with atherosclerosis. Atherosclerosis. 1987 May;65(1-2):1–11. [PubMed]
  • Niculescu F, Rus HG, Poruţiu D, Ghiurca V, Vlaicu R. Immunoelectron-microscopic localization of S-protein/vitronectin in human atherosclerotic wall. Atherosclerosis. 1989 Aug;78(2-3):197–203. [PubMed]
  • Theofilopoulos AN, Perrin LH. Lysis of human cultured lymphoblastoid cells by cell-induced activation of the properdin pathway. Science. 1977 Mar 4;195(4281):878–880. [PubMed]
  • Cheung NK, Walter EI, Smith-Mensah WH, Ratnoff WD, Tykocinski ML, Medof ME. Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro. J Clin Invest. 1988 Apr;81(4):1122–1128. [PMC free article] [PubMed]
  • Zalman LS, Wood LM, Müller-Eberhard HJ. Isolation of a human erythrocyte membrane protein capable of inhibiting expression of homologous complement transmembrane channels. Proc Natl Acad Sci U S A. 1986 Sep;83(18):6975–6979. [PMC free article] [PubMed]
  • Baker PJ, Adler S, Yang Y, Couser WG. Complement activation by heat-killed human kidney cells: formation, activity, and stabilization of cell-bound C3 convertases. J Immunol. 1984 Aug;133(2):877–881. [PubMed]
  • Panneerselvam M, Welt S, Old LJ, Vogel CW. A molecular mechanism of complement resistance of human melanoma cells. J Immunol. 1986 Apr 1;136(7):2534–2541. [PubMed]
  • Carney DF, Koski CL, Shin ML. Elimination of terminal complement intermediates from the plasma membrane of nucleated cells: the rate of disappearance differs for cells carrying C5b-7 or C5b-8 or a mixture of C5b-8 with a limited number of C5b-9. J Immunol. 1985 Mar;134(3):1804–1809. [PubMed]
  • Morgan BP, Dankert JR, Esser AF. Recovery of human neutrophils from complement attack: removal of the membrane attack complex by endocytosis and exocytosis. J Immunol. 1987 Jan 1;138(1):246–253. [PubMed]

Articles from The American Journal of Pathology are provided here courtesy of American Society for Investigative Pathology


Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


  • Compound
    PubChem Compound links
  • MedGen
    Related information in MedGen
  • PubMed
    PubMed citations for these articles
  • Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...